SGLT2 Inhibitor Cancer Risk Meta-Analysis: 28 RCTs and 98,297 Participants

Jing Teng's systematic review and meta-analysis assesses the long-term safety of Sodium-glucose cotransporter 2 (SGLT2) inhibitors regarding cancer risk in patients with Type 2 diabetes, heart failure, and chronic kidney disease. The analysis includes 28 randomized controlled trials with 98,297 participants, with studies published up to April 16, 2024. The results, including pooled risk ratios, are compiled in a DOCX document.

Use Cases

• Assessing the association between SGLT2 inhibitors and overall cancer risk based on pooled results from 28 RCTs.
• Evaluating drug safety for specific cancer types, such as breast or bladder cancer, as mentioned in the secondary outcomes.
• Conducting subgroup safety analyses for patient populations with heart failure or chronic kidney disease based on the reported risk ratios.
• Validating meta-analysis methodologies using the provided PROSPERO registration identifier and search strategy.

Strengths

• Includes results from 28 randomized controlled trials, a substantial evidence base.
• Analyzes data from 98,297 participants, providing a large sample size.
• Reports specific pooled risk ratios with 95% confidence intervals for primary and subgroup analyses.
• Uses a registered, systematic review methodology (PROSPERO CRD42024560310).

Limitations

• The dataset is a 36.1 KB DOCX document; the underlying tabular data (e.g., forest plots, study-level data) is not directly accessible in a structured format.
• Row and column-level details are unknown, limiting immediate analysis without manual data extraction from the document.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Jing Teng, via figshare.

Collection Method

Systematic review and meta-analysis of studies from PubMed, CENTRAL, Web of Science, and ClinicalTrials.gov.

Time Range

Studies published up to April 16, 2024.

Freshness

Last updated 2026-05-08 05:57:07; freshness should be verified.